Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2022-04-29 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2021 Annual Report Summary" of 瑞康医药集团股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2021, including revenue, profit, cash flow, business segment descriptions, shareholder information, and accounting data. The presence of comprehensive financial figures and business analysis confirms it is a financial report rather than a brief announcement or presentation. The document length (8671 characters) and content depth support classification as an Annual Report. Therefore, the appropriate filing type is Annual Report (10-K). FY 2021
2022-04-29 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a detailed audit-related report issued by a certified public accounting firm regarding non-operating fund occupation and other related party fund transactions of Ruikang Pharmaceutical Group Co., Ltd. It references the audit of the 2021 financial statements and includes specific financial data and reconciliations related to related party transactions. The document is issued by an accounting firm with a report number and date, and it contains substantive financial data and audit findings. It is not a full annual report but a standalone audit-related report focusing on a specific issue (related party fund occupation). Therefore, it fits the category of Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification. FY 2021
2022-04-29 Chinese
瑞康医药独立董事对第四届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 瑞康医药集团股份有限公司 regarding specific matters discussed at the 21st meeting of the 4th board of directors. It includes opinions on the 2021 internal control self-evaluation report, the 2021 profit distribution plan, and related party transactions and guarantees. The document references regulatory rules and internal control assessments but does not contain full financial statements or comprehensive financial data. It is a formal board/management related announcement expressing independent directors' opinions on board meeting matters rather than a full annual report or audit report. The document length is short (1269 characters), and it is not a report publication announcement or certification letter. Therefore, the best fitting category is Board/Management Information (MANG).
2022-04-29 Chinese
监事会关于同一控制下企业合并追溯调整财务数据的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed explanation from the supervisory board of 瑞康医药集团股份有限公司 regarding retrospective adjustments to financial data due to a business combination under common control. It includes extensive financial data adjustments to the consolidated balance sheet, income statement, and cash flow statement for the year 2020. The document references accounting standards and provides detailed financial figures reflecting the retrospective adjustments. This is not a full annual report but a specific audit-related explanation and adjustment disclosure concerning accounting treatment of a business combination under common control. It is a standalone audit-related report focusing on accounting principles and retrospective financial data adjustments, fitting the definition of an Audit Report / Information (AR). The document length (9279 characters) and content support this classification rather than a full Annual Report or other categories. FY 2020
2022-04-29 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 100% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report". It is issued by a certified public accounting firm and includes detailed information about the internal control evaluation of 瑞康医药集团股份有限公司 for the year ended December 31, 2021. The report includes the auditor's opinion on the effectiveness of internal controls related to financial reporting, management responsibilities, audit procedures, and detailed descriptions of internal control systems and their implementation. It is a standalone audit-related report focusing on internal control effectiveness, not a full annual report or financial statement. The document length is substantial (12,600 characters), and it contains substantive audit content rather than just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2021
2022-04-29 Chinese
同一控制下企业合并追溯调整的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed audit-related report issued by a certified public accounting firm regarding retrospective adjustments to previously disclosed financial statements due to a business combination under common control. It includes extensive financial data adjustments for prior periods, references to accounting standards, and an audit opinion with no reservations. The presence of audit report identifiers, CPA signatures, and detailed financial statement adjustments indicates this is a standalone audit report or special audit explanation rather than a full annual report or other filing. It is not a brief announcement or a certification letter but a substantive audit document focused on accounting treatment and financial statement restatement. Therefore, the document fits the category of Audit Report / Information (AR). FY 2021
2022-04-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.